[{"data":1,"prerenderedAt":435},["ShallowReactive",2],{"tool-healthcare-infervision":3,"footer-total":408,"related-healthcare-infervision":409},{"id":4,"title":5,"author":6,"bestFor":7,"body":8,"category":366,"cons":367,"cover":373,"date":374,"description":375,"draft":376,"extension":377,"meta":378,"navigation":379,"notFor":380,"path":381,"pricing":382,"pros":386,"region":392,"score":393,"scoreBreakdown":394,"seo":399,"stem":400,"tags":401,"toolName":231,"updated":374,"url":405,"vendor":406,"__hash__":407},"tools\u002Ftools\u002Fhealthcare\u002Finfervision.md","推想医疗 评测","元析评测","日 CT 检查量 200 例以上、影像科医师缺口明显的二甲与三甲医院",{"type":9,"value":10,"toc":338},"minimark",[11,15,23,26,29,66,69,74,77,80,84,87,90,94,97,100,103,106,109,112,116,119,123,126,130,133,137,140,144,147,150,214,217,220,295,301,305,309,312,316,319,323,326,329,332],[12,13,14],"h2",{"id":14},"结论先行",[16,17,18,22],"p",{},[19,20,21],"strong",{},"有条件推荐,总分 7.6,官网未公开报价,只能走销售咨询。"," 推想医疗做医学影像 AI,主力产品 InferRead 在 CT、DR 图像上标出可疑病灶,把检出结果写成结构化报告推回 PACS。医生不用换界面,阅片时旁边多一栏提示。官网写明产品拿到 NMPA、FDA、CE、UKCA、PMDA 五张准入,覆盖 30 多个国家、1000 多家机构。",[16,24,25],{},"边界要讲清楚。它不是诊断设备,结论要医生签字;它也不解决人力短缺,只把\"找病灶\"这一步提速。日检查量不到一百例的医院,省下的时间抵不上年服务费;PACS 都跑不顺的机构,装上也接不进去。",[12,27,28],{"id":28},"这篇评测基于什么数据",[30,31,32,39,45,54,60],"ul",{},[33,34,35,38],"li",{},[19,36,37],{},"官网",":2026-11 核对 infervision.com 首页与四个解决方案页,取得产品线(InferRead、InferOperate、InferCare、科研平台)、公司数据与联系方式。",[33,40,41,44],{},[19,42,43],{},"具体数字",":官网写明成立于 2016 年,已获批及在申专利 390+,SCI 核心论文 350+,覆盖 30 多个国家、1000 多家医疗机构。",[33,46,47,50,53],{},[19,48,49],{},"合规口径",[51,52],"ai",{}," 辅助诊断软件按第三类医疗器械管理,须取得注册证后方可在院内使用;影像接入遵循 DICOM 标准,报告回写多用 HL7 或院内集成引擎。",[33,55,56,59],{},[19,57,58],{},"价格政策",":部分省份把人工智能辅助诊断列为可加收的医疗服务价格项目,具体项目与标准以当地医保局文件为准,这一点直接影响医院的投入产出测算。",[33,61,62,65],{},[19,63,64],{},"实测声明",":我们没在真实科室装机,没用自有病例跑过检出率,也没拿到报价单。以下判断来自官网信息、公开文献与同类产品的落地经验。",[12,67,68],{"id":68},"核心功能",[70,71,73],"h3",{"id":72},"inferread检出与结构化报告","InferRead:检出与结构化报告",[16,75,76],{},"InferRead 的工作方式是:从 PACS 拉取检查图像,模型标出疑似病灶的位置、大小、类型,再生成一段结构化描述回写报告。以肺结节为例,输出通常包括结节位置、长径、密度类型、随访建议。",[16,78,79],{},"这里有个容易被忽略的细节:层厚。薄层 CT(1 毫米重建)和厚层图像的检出表现差别明显,医院如果为了省存储空间只留厚层,AI 的效果会打折。装机前最好用自家设备的历史病例跑一批对照。",[70,81,83],{"id":82},"与-pacs-的集成方式","与 PACS 的集成方式",[16,85,86],{},"影像 AI 落地的成败,八成在集成。常见三种方式:一是通过 DICOM 网关自动拉图,医生打开检查时结果已经在;二是医生在 PACS 里手动触发;三是独立网页端。",[16,88,89],{},"第一种体验最好,但要求厂商与 PACS 厂商配合开发接口,工期取决于 PACS 侧的排期。医院采购时要把\"与现有 PACS 的集成方式、由谁负责联调、工期多久\"写进合同,否则设备到了接不进去,一放就是半年。",[70,91,93],{"id":92},"inferoperate-与治疗环节","InferOperate 与治疗环节",[16,95,96],{},"InferOperate 面向治疗:手术规划、术中定位导航。比如胸外科术前用 AI 重建肺段血管与支气管,规划切除范围;骨科用 AI 做假体匹配与置入路径。",[16,98,99],{},"这块的技术门槛比筛查高,落地也更依赖临床科室的意愿。外科医生接受新工具的前提是\"不增加操作步骤\",所以这类产品通常要和手术导航设备、机器人厂商一起谈。",[70,101,102],{"id":102},"科研平台与商业逻辑",[16,104,105],{},"InferScholar 与 InferMatrix 给影像科做课题:数据标注、模型训练、结果验证。对以科研考核为压力的三甲影像科,这是加分项。",[16,107,108],{},"但要说清商业逻辑:影像 AI 目前主要靠两种方式回本,一是纳入当地医疗服务价格项目后按次收费,二是作为学科建设与评审的投入。前一种受政策限制,后一种算不清账。医院做预算时最好按\"效率提升折算人力\"来算,别把收费预期打得太满。",[12,110,111],{"id":111},"评分明细",[70,113,115],{"id":114},"功能完整度8010","功能完整度:8.0\u002F10",[16,117,118],{},"部位覆盖比多数同行走得宽,筛查、治疗、随访、科研四条线都有产品,证照覆盖也全。扣分在随访与结构化报告的深度:InferCare 相对轻,复杂随访仍要靠院内系统。",[70,120,122],{"id":121},"易用性7710","易用性:7.7\u002F10",[16,124,125],{},"医生端最大的优点是\"不换界面\",结果嵌在 PACS 里看,学习成本低。扣分在复核负担:假阳性提示会让人多看一眼,初期反而更慢,要两三个月才顺过来。",[70,127,129],{"id":128},"数据质量8110","数据质量:8.1\u002F10",[16,131,132],{},"输出字段结构化程度高,能直接进报告模板与科研数据库,随访对比也有依据。扣分在跨设备一致性:不同厂商 CT 的成像参数差异会影响结果,多院区统一部署时要分设备调参。",[70,134,136],{"id":135},"性价比6810","性价比:6.8\u002F10",[16,138,139],{},"按院区加年服务费,一家医院一年几十万是常见量级,而收费通道在多数省份没打开。算账只能按\"减少漏诊风险 + 节省阅片时间\"来算,财务上不硬。",[70,141,143],{"id":142},"客户支持7610","客户支持:7.6\u002F10",[16,145,146],{},"装机和培训有专人跟,版本更新含在服务费里,线上问题响应及时。扣分在集成联调:涉及第三方 PACS 时排期不完全由它控制,医院要自己盯进度。",[12,148,149],{"id":149},"定价说明",[151,152,153,169],"table",{},[154,155,156],"thead",{},[157,158,159,163,166],"tr",{},[160,161,162],"th",{},"项目",[160,164,165],{},"价格",[160,167,168],{},"说明",[170,171,172,184,194,204],"tbody",{},[157,173,174,178,181],{},[175,176,177],"td",{},"InferRead 单科室授权",[175,179,180],{},"未公开",[175,182,183],{},"按院区、装机科室、部位数量计价",[157,185,186,189,191],{},[175,187,188],{},"年服务费",[175,190,180],{},[175,192,193],{},"通常首年含在合同内,次年起按年收",[157,195,196,199,201],{},[175,197,198],{},"InferOperate",[175,200,180],{},[175,202,203],{},"与手术导航、机器人方案打包报价",[157,205,206,209,211],{},[175,207,208],{},"科研平台",[175,210,180],{},[175,212,213],{},"按科室授权或课题项目单独计价",[16,215,216],{},"2026-11 核对时,四个解决方案页只留咨询表单,没有一处标价。这类产品的报价差异主要来自三处:装机科室数量、覆盖部位、以及是否包含与 PACS 的定制集成。合同里建议确认三件事:模型升级是否含在年服务费内、新增科室的单价、以及停止合作后院内已产生的结构化报告归谁。",[12,218,219],{"id":219},"和竞品对比",[151,221,222,238],{},[154,223,224],{},[157,225,226,229,232,235],{},[160,227,228],{},"维度",[160,230,231],{},"推想医疗",[160,233,234],{},"联影智能",[160,236,237],{},"深睿医疗",[170,239,240,254,267,281],{},[157,241,242,245,248,251],{},[175,243,244],{},"定位",[175,246,247],{},"多部位影像 AI 加治疗延伸",[175,249,250],{},"设备厂商配套的影像 AI",[175,252,253],{},"影像 AI 与临床辅助",[157,255,256,259,262,265],{},[175,257,258],{},"起步价",[175,260,261],{},"未公开,年服务费",[175,263,264],{},"未公开,常与设备打包",[175,266,261],{},[157,268,269,272,275,278],{},[175,270,271],{},"强项",[175,273,274],{},"证照齐全、部位覆盖广",[175,276,277],{},"与自家设备深度绑定",[175,279,280],{},"肺结节与胸片产品成熟",[157,282,283,286,289,292],{},[175,284,285],{},"短板",[175,287,288],{},"收费通道依赖地方政策",[175,290,291],{},"跨品牌设备适配偏弱",[175,293,294],{},"治疗环节产品少",[16,296,297,300],{},[19,298,299],{},"怎么选",":院内设备品牌杂、要一次覆盖多个部位,推想医疗的适配面更宽;新院区整体采购联影设备、想少一家供应商,联影智能的打包方案更省事;主要诉求是肺结节筛查和胸片质控,深睿医疗的产品成熟度够用且谈价空间大。",[12,302,304],{"id":303},"faq","FAQ",[70,306,308],{"id":307},"q-装了-ai医生真的会用吗","Q: 装了 AI,医生真的会用吗?",[16,310,311],{},"A: 取决于结果放在哪。嵌进 PACS 阅片界面、打开检查就能看到,使用率通常能上去;要另开网页、另登录一次,三个月后基本没人点。采购时把\"集成方式\"当成和准确率同等重要的指标来谈。",[70,313,315],{"id":314},"q-买断还是按年付","Q: 买断还是按年付?",[16,317,318],{},"A: 影像 AI 主流是按年付,因为模型要持续迭代、还要跟着法规更新。买断听起来省钱,但两三年后模型落后、又拿不到升级,等于重新采购一次。合同里可以争取的是年服务费涨幅上限。",[70,320,322],{"id":321},"q-影像-ai-能向患者收费吗","Q: 影像 AI 能向患者收费吗?",[16,324,325],{},"A: 看当地政策。部分省份已把人工智能辅助诊断列入医疗服务价格项目,医院可按项目加收;多数地区还没有,只能作为内部效率工具。这一点直接决定投入产出,立项前先问当地医保局。",[12,327,328],{"id":328},"评测方法说明",[16,330,331],{},"元析评测围绕功能完整度、易用性、数据质量、性价比、客户支持五个维度打分,每项满分 10 分,加权折算总分。本篇的公司数据、产品线与准入信息核对于 2026-11 官网;官网未公示价格,文中不含任何金额,实际报价以销售方案与合同为准。",[16,333,334,337],{},[19,335,336],{},"最后更新",":2026-11-16",{"title":339,"searchDepth":340,"depth":340,"links":341},"",2,[342,343,344,351,358,359,360,365],{"id":14,"depth":340,"text":14},{"id":28,"depth":340,"text":28},{"id":68,"depth":340,"text":68,"children":345},[346,348,349,350],{"id":72,"depth":347,"text":73},3,{"id":82,"depth":347,"text":83},{"id":92,"depth":347,"text":93},{"id":102,"depth":347,"text":102},{"id":111,"depth":340,"text":111,"children":352},[353,354,355,356,357],{"id":114,"depth":347,"text":115},{"id":121,"depth":347,"text":122},{"id":128,"depth":347,"text":129},{"id":135,"depth":347,"text":136},{"id":142,"depth":347,"text":143},{"id":149,"depth":340,"text":149},{"id":219,"depth":340,"text":219},{"id":303,"depth":340,"text":304,"children":361},[362,363,364],{"id":307,"depth":347,"text":308},{"id":314,"depth":347,"text":315},{"id":321,"depth":347,"text":322},{"id":328,"depth":340,"text":328},"healthcare",[368,369,370,371,372],"官网没有价格与授权方式,预算只能靠销售给方案,横向比价困难","效果依赖图像质量,设备老旧、层厚偏厚时检出率下降,需要在自家机器上先验证","纳入物价收费的省份有限,多数医院只能算效率工具,算不出直接收入","AI 提示的假阳性会增加医生复核量,工作量的净节省要按病种分别估","科研平台功能与临床产品分离,想做课题还要单独采购与培训",null,"2026-11-16","推想医疗评测:官网未公开报价,按院区与年服务费谈,InferRead 做病灶检出并回写结构化报告,五大市场准入齐。适合影像科工作量大、想给报告提速的二甲以上医院,不适合没有 PACS 基础的机构。",false,"md",{},true,"没有 PACS 或影像归档不规范、连 DICOM 都跑不通的机构","\u002Ftools\u002Fhealthcare\u002Finfervision",{"free":376,"startingPrice":339,"currency":383,"billingPeriod":384,"notes":385},"CNY","年","官网未公开报价,需联系销售。2026-11 核对 infervision.com 首页与四个解决方案页,未见价格页或套餐表,只有「产品与合作咨询」表单与 010-86462323。此类影像 AI 按院区、装机科室数、年服务费计价,常见形态是首年含实施、次年起按年续费。2026-11 核对。",[387,388,389,390,391],"官网写明产品取得 NMPA、FDA、CE、UKCA、PMDA 五大市场准入,国内影像 AI 里证照覆盖较全","InferRead 覆盖肺、心脑血管、乳腺、骨关节多个部位,不是只做肺结节一个方向","检出结果回写结构化报告并挂到 PACS,医生在原有阅片界面里看结论,不用切系统","InferOperate 把 AI 延伸到了治疗环节,提供手术规划与术中定位,产品不只停在筛查","InferScholar、InferMatrix 两个科研平台给影像科做课题,数据标注与模型训练能留在院内","cn",7.6,{"features":395,"ease":396,"data":397,"price":398,"support":393},8,7.7,8.1,6.8,{"title":5,"description":375},"tools\u002Fhealthcare\u002Finfervision",[402,403,404,231],"医疗健康","医学影像AI","辅助诊断","https:\u002F\u002Fwww.infervision.com","推想医疗科技股份有限公司","4eC8OWUSVbz7_uIW1l7q8ywbEvTH6dPicheY9iMt5dk",1016,[410,419,427],{"path":411,"toolName":412,"description":413,"score":414,"pricing":415,"vendor":417,"date":418,"category":366},"\u002Ftools\u002Fhealthcare\u002Fdxy","丁香医生","丁香医生是丁香园旗下院外健康平台,集团官网写明注册医师 450 万+,App 首次问诊 9.9 元起,科普内容有医生审稿。它适合药企做患者教育、个人问小病,不适合当医院信息系统用,也不做医保结算,问诊只是轻咨询。",8.6,{"free":379,"startingPrice":339,"currency":383,"billingPeriod":384,"notes":416},"C 端免费使用,问诊按次付费,App Store 官方文案写明首次问诊 9.9 元起,复诊单价由接诊医生设定。药企内容合作、医院科普项目等机构业务官网未公开标准报价,需联系销售。价格核对时间 2026-11。","丁香园","2026-11-04",{"path":420,"toolName":421,"description":422,"score":423,"pricing":424,"vendor":421,"date":426,"category":366},"\u002Ftools\u002Fhealthcare\u002Falihealth","阿里健康","阿里健康是阿里系医药与医疗平台,官网披露天猫健康 4.83 万商家、大药房 123 万 SKU、码上放心服务 7100 家流通企业。强项在商家规模与药品追溯合规,适合药企做渠道,不适合想买独立 HIS 的医院,云医院由合作方实施。",8.5,{"free":376,"startingPrice":339,"currency":383,"billingPeriod":384,"notes":425},"C 端购药与问诊按件、按次付费,无独立订阅套餐。天猫健康入驻涉及保证金与技术年费,码上放心按追溯码用量或年度服务计费,官网均未公开标准报价,需联系销售。价格核对时间 2026-11。","2026-10-22",{"path":428,"toolName":429,"description":430,"score":431,"pricing":432,"vendor":429,"date":434,"category":366},"\u002Ftools\u002Fhealthcare\u002Fhaodf","好大夫在线","好大夫在线收录 10450 家医院、931617 位大夫,App 写明 28 万医生入驻、服务 8900 万患者。它是医生个人品牌的入口,问诊价格由医生定,适合副主任以上医生和找专病专家的患者。不适合急诊,入驻免费但抽成不公开,签约前要多看同城案例。",8.3,{"free":379,"startingPrice":339,"currency":383,"billingPeriod":384,"notes":433},"患者浏览医生主页、看评价免费,图文、电话、视频问诊按医生自报价付费,私人医生与优选会员为付费服务。医生入驻不收费。平台抽成比例与机构合作报价官网未公开标准报价,需联系销售。价格核对时间 2026-11。","2026-10-29",1794788232408]